Back to search
Advanced Solid Tumors Harboring KRAS G12C Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors Harboring KRAS G12C Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors Harboring KRAS G12C Mutation trials you may qualify forThe purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This stu…
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cell…
Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alt…
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity…
This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation…
This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G…
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent…